PSMA PET-CT For Staging High-Risk Prostate Cancer: An Interview With Michael Hofman, MBBS

Results from a multicenter, randomized study (ANZCTR12617000005358) have shown that prostate-specific membrane antigen (PSMA) positron emission tomography-computed tomography (PET-CT) has superior efficacy in staging men with high-risk localized prostate cancer compared with conventional imaging using computed tomography (CT) and bone scan. In an interview with i3 Health, lead investigator from the study, Michael Hofman, MBBS, discusses challenges of treating patients with high-risk prostate can...
Continue reading

FDA Approval: Pembrolizumab for Head and Neck Cancer

Pembrolizumab (Keytruda®, Merck) is now approved by the FDA for head and neck squamous cell carcinoma as first-line treatment in combination with platinum and 5-fluorouracil. Pembrolizumab is already FDA approved to treat advanced non-small cell lung cancer, advanced urothelial bladder cancer, classical Hodgkin lymphoma, primary mediastinal B-cell lymphoma, and many other cancers. This immunotherapy drug inhibits programmed cell death protein 1 (PD-1) in order to increase the body's ability to a...
Continue reading

Copyright ┬ę 2020 i3 Health. All rights reserved.